Adverse impact of bone metastases on clinical outcomes of patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors

BACKGROUND: Bone metastasis (BoM) is common in patients with advanced non‐small cell lung cancer (NSCLC) and considered as one of the negative prognostic factors. However, the impact of BoM on clinical outcomes of patients with advanced NSCLC treated with immune checkpoint inhibitors (ICIs) remains...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xing, Wang, Lei, Chen, Shanhao, Zhou, Fei, Zhao, Jing, Zhao, Wencheng, Su, Chunxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529562/
https://www.ncbi.nlm.nih.gov/pubmed/32779372
http://dx.doi.org/10.1111/1759-7714.13597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529562/
https://www.ncbi.nlm.nih.gov/pubmed/32779372
http://dx.doi.org/10.1111/1759-7714.13597

Ejemplares similares